Affibody Medical Investor Relations
Categories:
Navigation:
Non-Regulatory
March 8, 2018
Affibody Raises SEK 200m in Rights Issue
Solna, Sweden, March 8, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced the outcome of the rights issue that...
Read more
February 26, 2018
Affibody Announces Participation in the CellNova Center
Solna, Sweden, February 26, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced its participation in the CellNova Center.
February 23, 2018
Year End Report 2017
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...
December 1, 2017
Bästa aktieägare i Affibody Medical AB
Vid extra bolagsstämma i bolaget den 23 november i år beslöts att genomföra en nyemission av aktier i bolaget.
November 17, 2017
Interim Report – January to September 2017
November 8, 2017
Kallelse till extra bolagsstämma
Aktieägarna i Affibody Medical AB (publ) kallas härmed till extra bolagsstämma torsdagen den 23 november 2017 kl 16.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.
September 6, 2017
Affibody Announces Presentation of Interim Data from Phase I/II Clinical Trial of ABY-035 at European Academy of Dermatology and Venereology
Solna, Sweden, September 6, 2017. Affibody AB (“Affibody”), a clinical stage next generation biopharmaceutical company developing a portfolio of innovative drug projects, today announced that interim data from the...
August 23, 2017
Interim Report – January to June 2017
May 24, 2017
Kallelse till årsstämma
Aktieägarna i Affibody Medical AB (publ) kallas härmed till årsstämma torsdagen den 29 juni 2017 klockan 13.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.
